🇺🇸 FDA
Pipeline program

ADX-102 Ophthalmic Drops (0.5%)

ADX-102-AC-004

Phase 2 small_molecule completed

Quick answer

ADX-102 Ophthalmic Drops (0.5%) for Conjunctivitis, Allergic is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aldeyra Therapeutics
Indication
Conjunctivitis, Allergic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials